Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CRIS

Curis Inc

Dec 13 • 04:00PM ET

3.57

Dollar change -0.15
Percentage change -4.03	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC TGTX KURA BIVI FATE ASND RIGL GOSS XOMA

| Held by: VTI VXF IWC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.81	Insider Own	8.28%	Shs Outstand	8.47M	Perf Week	-7.51%
Market Cap	29.01M	Forward P/E	-	EPS next Y	-4.38	Insider Trans	0.00%	Shs Float	7.77M	Perf Month	-9.16%
Income	-45.48M	PEG	-	EPS next Q	-1.34	Inst Own	23.79%	Short Float	0.95%	Perf Quarter	-39.18%
Sales	10.26M	P/S	2.83	EPS this Y	22.88%	Inst Trans	-5.34%	Short Ratio	1.33	Perf Half Y	-56.09%
Book/sh	-1.45	P/B	-	EPS next Y	36.61%	ROA	-68.68%	Short Interest	0.07M	Perf Year	-69.92%
Cash/sh	2.57	P/C	1.39	EPS next 5Y	-	ROE	-436.16%	52W Range	3.51 - 17.49	Perf YTD	-72.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.56%	ROI	-222.53%	52W High	-79.59%	Beta	3.37
Dividend TTM	-	Quick Ratio	1.22	Sales past 5Y	-0.68%	Gross Margin	92.79%	52W Low	1.71%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	1.22	EPS Y/Y TTM	16.44%	Oper. Margin	-465.42%	RSI (14)	35.24	Volatility	9.24% 9.40%
Employees	49	Debt/Eq	-	Sales Y/Y TTM	0.44%	Profit Margin	-443.35%	Recom	1.40	Target Price	21.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	20.22%	Payout	-	Rel Volume	0.85	Prev Close	3.72
Sales Surprise	29.26%	EPS Surprise	7.10%	Sales Q/Q	3.46%	Earnings	Nov 14 BMO	Avg Volume	55.66K	Price	3.57
SMA20	-10.62%	SMA50	-20.27%	SMA200	-55.09%	Trades		Volume	47,408	Change	-4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Truist	Buy	$26
Apr-04-22	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-13-21	Initiated	Raymond James	Outperform	$15
Mar-25-21	Initiated	B. Riley Securities	Buy	$19
Jul-29-20	Initiated	Laidlaw	Buy	$5
Jul-17-20	Initiated	Cantor Fitzgerald	Overweight	$4
Oct-24-17	Initiated	Guggenheim	Buy	$7
Mar-02-16	Initiated	Sun Trust Rbsn Humphrey	Buy	$3
Nov-09-15	Reiterated	ROTH Capital	Buy	$6 → $5
Aug-11-15	Initiated	FBR Capital	Outperform	$6
Jan-22-15	Reiterated	Oppenheimer	Outperform	$3 → $5
Jan-21-15	Reiterated	ROTH Capital	Buy	$10 → $6
May-09-14	Reiterated	Oppenheimer	Outperform	$4.50 → $3
Oct-02-13	Initiated	Robert W. Baird	Outperform	$7
Sep-30-13	Initiated	Chardan Capital Markets	Buy	$6
Nov-14-12	Initiated	Stifel Nicolaus	Hold
Jan-31-12	Reiterated	Summer Street Research	Buy	$5 → $7
Jan-31-12	Reiterated	Brean Murray	Buy	$5 → $6
Dec-09-11	Initiated	Oppenheimer	Outperform	$6
Oct-06-11	Initiated	Summer Street Research	Buy	$5

Show Previous Ratings

Dec-10-24 08:00AM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire)
Nov-15-24 02:37AM	Q3 2024 Curis Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... (GuruFocus.com)
Nov-14-24 09:10AM	Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:09AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Loading…
08:00AM	Curis Provides Third Quarter 2024 Business Update (PR Newswire)
Nov-13-24 07:31AM	Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-07-24 08:00AM	Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 (PR Newswire)
Nov-02-24 11:20AM	Curis price target lowered to $20 from $26 at H.C. Wainwright (TipRanks)
Oct-29-24 06:04AM	Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement (PR Newswire) -5.89%
Oct-09-24 03:42PM	Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... (GuruFocus.com)
Sep-23-24 08:30AM	Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer (PR Newswire)
Sep-17-24 07:30AM	Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference (PR Newswire) +5.11%
Sep-04-24 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-01-24 09:10AM	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.85%
08:07AM	Loading…
08:07AM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Second Quarter 2024 Financial and Operating Update (PR Newswire)
Jul-25-24 08:00AM	Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 (PR Newswire)
Jul-10-24 07:30AM	Curis to Present at Upcoming Healthcare Conference in July (PR Newswire)
Jul-09-24 12:00PM	What Makes Curis (CRIS) a New Buy Stock (Zacks)
Jul-08-24 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-14-24 04:00PM	Curis Announces Additional Data from TakeAim Leukemia Study (PR Newswire) -17.14%
May-10-24 08:00AM	Curis to Present Updated Data from the TakeAim Leukemia Study (PR Newswire)
May-08-24 11:39AM	Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 12:53PM	CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:08AM	Curis: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides First Quarter 2024 Business Update (PR Newswire)
Apr-30-24 08:00AM	Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 (PR Newswire)
Apr-05-24 08:43AM	Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength? (Zacks)
07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07:30AM	Loading…
Apr-04-24 07:30AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire) +19.48%
Feb-09-24 10:10AM	Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-08-24 08:11AM	Curis: Q4 Earnings Snapshot (Associated Press Finance) +13.42%
08:00AM	Curis Provides Fourth Quarter 2023 Business Update (PR Newswire)
Feb-01-24 08:00AM	Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 (PR Newswire)
Jan-05-24 08:00AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -9.87%
Dec-12-23 08:00AM	Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study (PR Newswire) +5.61%
Dec-11-23 08:00AM	Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference (PR Newswire) -8.89%
Dec-06-23 08:00AM	Curis Announces Three Presentations at ASH (PR Newswire) +16.50%
Dec-05-23 08:00AM	Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma (PR Newswire)
Nov-03-23 10:26AM	Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:03AM	Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year (GuruFocus.com)
Nov-02-23 08:19AM	Curis: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Curis Provides Third Quarter 2023 Business Update (PR Newswire)
Oct-30-23 10:00AM	2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.35%
Oct-26-23 08:30AM	Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 (PR Newswire)
Oct-06-23 08:56AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-22-23 03:15AM	Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-12-23 08:00AM	Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer (PR Newswire)
Sep-06-23 08:13AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire)
Aug-05-23 05:57AM	Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:45PM	Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.82%
04:43PM	Curis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Curis Provides Second Quarter 2023 Business Update (PR Newswire)
Jul-27-23 06:25PM	Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 (PR Newswire)
Jul-06-23 08:01AM	FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID (PR Newswire)
08:00AM	Curis Announces $15.1 Million Registered Direct Offering (PR Newswire)
Jun-30-23 06:50AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 50% over the last five years (Simply Wall St.)
Jun-06-23 06:54AM	Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount? (Simply Wall St.)
May-15-23 11:33AM	Is Curis (NASDAQ:CRIS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-05-23 07:30AM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-04-23 05:45PM	Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Curis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Curis Provides First Quarter 2023 Business Update (PR Newswire)
Apr-27-23 04:01PM	Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023 (PR Newswire) +8.76%
Apr-17-23 08:12AM	Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth (Simply Wall St.)
Apr-05-23 08:13PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-03-23 08:00AM	Curis to Present at Upcoming Healthcare Conferences in April (PR Newswire)
Mar-14-23 11:02AM	Curis, Inc. (NASDAQ:CRIS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 10:21PM	Q4 2022 Curis Inc Earnings Call (Thomson Reuters StreetEvents) -8.40%
09:15AM	Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Curis Provides Fourth Quarter 2022 Business Update (PR Newswire)
Mar-08-23 07:09PM	Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call (PR Newswire)
Mar-02-23 04:01PM	Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023 (PR Newswire) +8.32%
Jan-20-23 10:09AM	Investors in Curis (NASDAQ:CRIS) have unfortunately lost 80% over the last five years (Simply Wall St.)
Dec-12-22 10:00AM	Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS (PR Newswire) -15.53%
Dec-05-22 11:08PM	Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia (PR Newswire)
Nov-12-22 07:43AM	Curis Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 02:30PM	This biotech just laid off 30% of its staff. The CEO called the move 'counterintuitive' (American City Business Journals) +13.60%
Nov-09-22 05:45PM	Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.44%
04:01PM	Curis Provides Third Quarter 2022 Business Update (PR Newswire)
08:27AM	Here's Why We're Watching Curis' (NASDAQ:CRIS) Cash Burn Situation (Simply Wall St.)
Nov-07-22 04:01PM	Curis Announces Three Presentations at SITC 2022 (PR Newswire)
Nov-02-22 04:00PM	Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022 (PR Newswire)
Oct-07-22 04:01PM	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.26% -5.18%
Oct-03-22 04:01PM	Curis Announces Date for the 1st Symposium on IRAK4 in Cancer (PR Newswire) +17.20%
Sep-19-22 09:16PM	Curis Announces Date for the 2nd Annual VISTA Symposium (PR Newswire) -5.51% -6.24%
Sep-07-22 08:00AM	Curis to Present at Upcoming Healthcare Conferences in September (PR Newswire) +9.99%
Aug-31-22 12:53PM	Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study (Zacks)
Aug-30-22 08:52AM	Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold (Benzinga) -9.82%
08:00AM	FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study (PR Newswire)
Aug-19-22 12:25PM	Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain (Zacks) -7.14%
Aug-18-22 08:49AM	FDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled (Benzinga) +20.00%
08:00AM	FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib (PR Newswire)
Aug-13-22 10:05AM	Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this past week (Simply Wall St.)
Aug-05-22 03:30AM	Curis (CRIS) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 06:25PM	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Curis Reports Second Quarter 2022 Financial Results and Business Update (PR Newswire)
Jul-29-22 04:00PM	Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jul-28-22 04:00PM	Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 (PR Newswire) -5.61%

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRIS

Curis Inc

Upgrade your FINVIZ experience